AI English summary of an SEC filing — figures as filed
CVS Health CVSCVS Health said total revenues for the three months ended March 31, 2024 rose $3.2 billion, or 3.7%, from a year earlier. It said growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments drove the increase, partly offset by a decline in the Health Services segment.
Key points
AI summaryCVS Health said total revenues for the three months ended March 31, 2024 rose $3.2 billion, or 3.7%, from a year earlier. It said growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments drove the increase, partly offset by a decline in the Health Services segment.
The company said operating income fell $1.2 billion, or 34.1%, over the 3 months. It said the Health Care Benefits segment's MBR rose to 90.4% from 84.6% a year earlier. The company cited increased Medicare utilization and the decline in its 2024 Medicare Advantage star ratings as factors.
The company said total revenues for the Health Services segment fell $4.3 billion, or 9.7%, over the 3 months. It cited the loss of a large client and pharmacy client price improvements as the main factors. It also said pharmacy claims on a 30-day adjusted basis fell 21.2%.
The company said net cash provided by operating activities for the 3 months fell $2.5 billion from a year earlier. It attributed the decline mainly to the early receipt of $5.1 billion in CMS payments that had been received in April of the prior year. As of March 31, 2024, commercial paper outstanding was $2.7 billion.
Key figures
Quarter ended March 31, 2024
- Revenue
- $88.4B
- Operating income
- $2.3B
- Net income
- $1.1B
- EPS
- $0.88
- Operating cash flow
- $4.9B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q1 2024 Total Revenues Up $3.2 billion
CVS Health said total revenues for the three months ended March 31, 2024 rose $3.2 billion, or 3.7%, from a year earlier. It said growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments drove the increase, partly offset by a decline in the Health Services segment.
Source · Based on the MD&A text of the filing
Operating Income Down $1.2 billion; MBR at 90.4%
The company said operating income fell $1.2 billion, or 34.1%, over the 3 months. It said the Health Care Benefits segment's MBR rose to 90.4% from 84.6% a year earlier. The company cited increased Medicare utilization and the decline in its 2024 Medicare Advantage star ratings as factors.
Source · Based on the MD&A text of the filing
Health Services Revenue Down $4.3 billion
The company said total revenues for the Health Services segment fell $4.3 billion, or 9.7%, over the 3 months. It cited the loss of a large client and pharmacy client price improvements as the main factors. It also said pharmacy claims on a 30-day adjusted basis fell 21.2%.
Source · Based on the MD&A text of the filing
Operating Cash Flow Down $2.5 billion; CP at $2.7 billion
The company said net cash provided by operating activities for the 3 months fell $2.5 billion from a year earlier. It attributed the decline mainly to the early receipt of $5.1 billion in CMS payments that had been received in April of the prior year. As of March 31, 2024, commercial paper outstanding was $2.7 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…